Research Report on Gilead Sciences, Inc. and Bristol-Myers Squibb Company - New Innovations Facilitate Recovery
July 20 2011 - 9:00AM
Marketwired
Today, www.EquityMarketsInc.com announced its research report
highlighting Gilead Sciences, Inc. (NASDAQ: GILD) and Bristol-Myers
Squibb Company (NYSE: BMY). Full content and research is available
at www.EquityMarketsInc.com/research.php.
This sector demonstrates renewed investor interest as new and
lucrative therapies come to market. The FDA approved the first new
drug in 50 years to treat the auto-immune disorder lupus in March
2011, and we expect approval of new treatments for the Hepatitis C
virus around mid-year. The 2010 health care reform act authorized
by the FDA, will establish a regulatory pathway for approving
"biosimilar" drugs, which in turn will increase production and
shorten FDA approval times. Pharmaceuticals should remain one of
the widest-margin industries, with prospects enhanced by
demographic growth in the elderly and new drugs stemming from
discoveries in genomics and biotechnology.
Equity Markets has reviewed Gilead Sciences, Inc. as a
biopharmaceutical company focused on the development and
commercialization of human therapeutics for life threatening
diseases. The Company has operations in North America, Europe and
Asia Pacific. The Company's products include Truvada, Atripla,
Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and
Cayston. Its products are marketed through its commercial teams
and/or in conjunction with third-party distributors and corporate
partners. The full research report on Gilead Sciences, Inc.
(NASDAQ: GILD) is available here:
www.EquityMarketsInc.com/researchfile4634.php.
Equity Markets is covering Bristol-Myers Squibb Company as it is
engaged in the discovery, development, licensing, manufacturing,
marketing, distribution and sale of pharmaceutical products on a
global basis. The Company's products are sold worldwide, primarily
to wholesalers, retail pharmacies, hospitals, government entities
and the medical profession. It manufactures products in the United
States, Puerto Rico and in eight foreign countries. The Company's
pharmaceutical products include chemically-synthesized drugs, or
small molecules, and an increasing portion of products produced
from biological processes called biologics. The full research
report on Bristol-Myers Squibb Company (NYSE: BMY) is available
here: www.EquityMarketsInc.com/researchfile4891.php.
About Equity Markets Our mission at Equity Markets is to be the
best source of content and research, while educating, enlightening
and informing investors. Equity Markets combines street smart
analysts and professional market researchers to provide investors
with detailed company profiles and market coverage.
Contact: Samuel Littman Email Contact
www.EquityMarketsInc.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024